University of Sydney spin-off Elastagen has been sold to pharma company Allergan for US$95m, with further payments if the technology reaches the market. Elastagen is a synthetic spray-on skin for use in surgical wound repair and scar remodelling. The company was founded by UniSyd biochemist Tony Weiss.
Campus Morning Mail is an independent newsletter written and published by Stephen Matchett, formerly a long-serving journalist at The Australian newspaper. The daily e-news column receives no undisclosed funding or other assistance from any organisation or individual.
Subscribe